Pioglitazone, a well-tolerated FDA-approved thiazolidinedione (TZD) and PPARγ-agonist, demonstrates a high affinity for both PPARγ isoforms (1 and 2) [21], which are expressed in both humans and mice [22,23], and is indicated for the treatment of insulin resistance in type-2 diabetes mellitus [24]. This evidence concerns the gene PPARG and diabetes mellitus.